The 8 Reasons we Invested in EMD
Next Investors Sep 05, 2023
In today's note we deep dive into the 8 reasons we Invested in Emyria (ASX:EMD). EMD is an integrated clinical drug development and care delivery company whose primary area of focus is on psychedelics such MDMA, psilocybin and more recently, ketamine for treatment of mental health disorders
VUL continues to execute as sustainable lithium demand surges. So what’s next?
Next Investors Dec 21, 2021
Our investment Vulcan Energy Resources (ASX:VUL) has delivered everything it said they would do over the two years since we first invested. Heading into 2022, the company shows no signs of slowing down in achieving dual production of renewable energy and battery quality lithium chemicals with net zero carbon footprint.
Promising Results so Far… But there is Some More Work to Do…
Next Investors Mar 29, 2021
Today 88 Energy (ASX: 88E) announced the interpretation of its ‘logging while drilling’ data. The progress results to date indicate multiple potentially hydrocarbon bearing zones have been encountered whilst drilling.
Amateur investor advice and … two stocks to watch
Finfeed Archived Mar 26, 2021
With the Deliveroo IPO on the horizon, a surge in the number of new investors jumping on the opportunity is a foregone conclusion, however it is essential for these investors to learn how the system works before engaging with it.
Tell Me Why: The 10 Reasons We Invested in ONE
Next Investors Mar 19, 2021
Last Friday we announced our 2021 Tech Pick of the Year, Oneview Healthcare plc (ASX: ONE) - a healthcare technology company that enables ‘virtual care’ at the bedside for hospital patients. We promised that we would provide further analysis on why we have made such a large, long term investment and called ONE our 2021 Tech Pick of the Year…
Short Term Trade Update: What’s Happening to the CPH Share Price?
Next Investors Dec 02, 2020
We put out a short note on Creso Pharma (ASX: CPH) to some of you that might have previously invested in the stock and not had a positive experience. After a couple of false starts, our plan is to ride this momentum over the coming weeks and hopefully recoup some of our previous losses.
We are Rolling the Dice on this One…
Next Investors Oct 13, 2020
Long term Creso Pharma (ASX: CPH) shareholders have had a rough ride in the last 12 months. Last week the $20M capped CPH raised circa A$9M at $0.0291 per share, finally extinguishing the company’s debt and ridding the company of major con note holders that were hampering any share price appreciation.
Investing in Australian tech stocks
Finfeed Archived Oct 02, 2020
The ASX is well regulated and lists some of the world’s best companies: so, while some world markets may outperform our market for short periods, over the long term it not only holds its weight but outperforms nearly all other world markets in terms of return.
Don't overestimate your knowledge in the stock market
Finfeed Archived May 01, 2020
According to many surveys conducted by the ASX, it is common to find around 50 per cent of adult Australians believe they are very knowledgeable or somewhat knowledgeable when it comes to investing in shares. Are they overestimating their abilities?